A morphomolecular classification of malignant pleural mesothelioma
Lynnette Fernandez-Cuesta, PhD, International Agency for Research on Cancer (IARC-WHO), Lyon, France, discusses how the introduction of a morphomolecular classification of malignant pleural mesothelioma (MPM) could impact clinical management and treatment approaches for this patient population. The recent Omics project published in Nature Genetics suggests a paradigm shift in diagnosing and treating malignant pleural mesothelioma, the findings indicating the need to move away from the current morphological classification and consider a continuum of molecular variation. The study identified four key factors, including morphology, diploidy, immune interaction, and CPG island methylation, as crucial in understanding the disease. Dr Fernandez-Cuesta emphasizes future studies should focus on validating biomarkers to incorporate these factors into clinical treatment. The tumors were classified into three phenotypes representing specialized functions: cell division, tumor immune interaction, and cell cooperation. Immunotherapies may be more effective for tumors specialized in the immune interaction, while targeted therapies require further investigation using advanced techniques like single-cell sequencing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found